Monthly letter · News · Topics · Identity · Dispatches · Est. 2026

Where the Real You Learns to Live, not Just Stand Up

TheSignal

Dispatch · Mind & Body

Early weeks of treatment and abstinence: craving in placebo groups of nine trials and a small brain-metabolism study of drinkers

A July 2026 meta-analysis found craving fell in placebo groups of addiction medication trials. A September 2026 imaging study compared brain acetate use in light drinkers, heavy drinkers and people in early and long-term abstinence. Both are small on key groups.

James H. TippinsThe Autonomy Commission
DispatchMind & Body
SourcesThe Journal of Clinical Psychiatry, via PsyPost (Jul 31, 2026) · Neuropsychopharmacology, via PsyPost (Sep 9, 2026)

On July 31, 2026, PsyPost published an article by Eric W. Dolan on a systematic review and meta-analysis in The Journal of Clinical Psychiatry by Pim B. van der Meer and colleagues. From almost 2,000 records, nine randomized, double-blind trials of oral treatments were included: five in alcohol dependence, two in cocaine dependence and two in methamphetamine use. The placebo groups held 495 patients (300, 88 and 107). Self-rated craving fell across all three groups after at least four weeks, with a statistically reliable drop in alcohol and non-significant drops in cocaine and methamphetamine, where the estimates were uncertain. The article states there were only two studies each for cocaine and methamphetamine, that trials differed in length, patients and questionnaires, that blinding was rarely checked, and that the placebo effect cannot be separated from the natural course of the condition.

On September 9, 2026, PsyPost published an article by Eric W. Dolan on a study in Neuropsychopharmacology led by Chathura Kumaragamage and Graeme F. Mason, funded by the National Institute on Alcohol Abuse and Alcoholism according to the article. It compared 13 light drinkers, 15 heavy drinkers, 6 people abstinent for at least six months and a group in inpatient detoxification, with 9 usable scans at about one week of abstinence and 10 at about one month, and 7 scanned at both. Using a labeled acetate infusion and magnetic resonance spectroscopy, in the detox group at about one week, brain acetate oxidation was 64% lower than in heavy drinkers and 41% lower than in the long-term recovery group, heavy drinkers were 58% higher than light drinkers, and detox-group acetate use rose 43% by one month. The article states the groups were small, drinking was self-reported and acetate was given intravenously unlike the body's gradual supply.

Read together, one study asks how much craving eased with only a dummy pill, and the other asks how brain energy use looked at one week and one month without alcohol. Neither tracked the people around the patients or what they did in daily life. Both are about early weeks, and both rest on small groups.

◆ My Take

Early weeks in two samples

Both pages describe change in the first weeks. In the meta-analysis, craving fell in placebo groups, reliably so for alcohol. In the imaging study, in the detox group, brain acetate use at one week was well below that of heavy drinkers and the article reports it had increased 43% when retested at one month.

The pages measure craving ratings and a brain tracer, and the people in them appear as numbers on those two measures.

◆ If this is your question

Work on it out loud.

Free Mind Thursday is my weekly live call, and it costs nothing. Sign up at beyondunbound.com/freemind. Or get the next issue of The Signal free, below.